Mereo BioPharma Group plc Notice of AGM (2404C)
June 24 2016 - 6:47AM
UK Regulatory
TIDMMPH
RNS Number : 2404C
Mereo BioPharma Group plc
24 June 2016
24 June 2016
NOTICE OF ANNUAL GENERAL MEETING
Mereo BioPharma Group plc ("Mereo" or the "Company") (AIM:MPH),
a UK-based specialty biopharmaceutical company, gives notice of the
following:
-- the Notice of Annual General Meeting ("AGM") and Form of
Proxy have been sent to shareholders. The Notice of AGM is also
available in the Financial Calendar page of the Company's website;
and
-- that its AGM will be held on Monday 18 July 2016 at the
offices of Proskauer Rose (UK) LLP, 110 Bishopsgate, London EC2N
4AY at 10.00 a.m.
Enquiries:
+44 (0)333
Mereo BioPharma Group plc 023 7319
Denise Scots-Knight, Chief Executive
Officer
Richard Bungay, Chief Financial
Officer & COO
Cantor Fitzgerald Europe (Nominated +44 (0)20
Adviser and Broker) 7894 7000
Phil Davies
Will Goode
Rick Thompson
Callum Butterfield
+44 (0)20
RBC Capital Markets (Joint Broker) 7653 4000
Paul Tomasic
Rupert Walford
Thomas Stockman
Laura White
FTI Consulting (Public Relations +44 (0)20
Adviser) 3727 1000
Ben Atwell
Simon Conway
Brett Pollard
About Mereo
Mereo is a UK-based specialty biopharmaceutical company focused
on the development of innovative medicines that aim to address
unmet medical needs in rare and specialty disease areas and improve
patient quality of life.
Pharmaceutical companies face increasingly difficult choices in
the allocation of internal resources to their drug development
programs. With significant P&L constraints and rich pipelines
it has become increasingly difficult for many companies to fully
fund and advance development all of their drug candidates,
especially beyond Phase 2. Mereo has been formed to take advantage
of the global pharmaceutical industry's drive for creative ways to
progress their clinical development pipelines.
Mereo's initial mid-late stage portfolio consists of three
exceptionally well characterised novel products for the treatment
of diseases with considerable unmet medical need, which it acquired
from Novartis Pharmaceuticals in July 2015. Each of these
programmes has a comprehensive dataset for both pre-clinical and
proof-of-concept clinical studies. Since that time the Company has
initiated a Phase 2 study and a Phase 2b study in relation to two
of the product candidates in 2016 and intends to commence
registration studies during H2 2016 for the third product
candidate. Additional product opportunities are under
evaluation.
Mereo's focus is the development of innovative medicines that
have the potential to significantly transform the lives of patients
suffering from rare and other specialised conditions around the
world. To do this, the Company depends on the combination of its
team's expertise in selecting and acquiring product opportunities,
creating value in the development pipeline and structuring creative
transactions. Mereo's internal expertise is complemented by a
unique partnership with a leading global CRO, ICON.
Mereo combines the operational discipline and efficiency of a
small company with the financial resources to conduct comprehensive
clinical studies. Mereo will rapidly progress each of the products
through further value inflection points before partnering or
divesting its products. The Company also has the option to directly
commercialise products, for example in orphan disease
indications.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAAKQDQDBKDPAB
(END) Dow Jones Newswires
June 24, 2016 07:47 ET (11:47 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024